Combination vaccine safety after approval — reviewing VAERS reports and post-licensure surveillance data for multi-antigen vaccines including Pediarix, Pentacel, ProQuad, and Vaxelis.
Post-licensure findings relevant to the combination vaccines on the US childhood schedule. The most significant post-licensure question for combination vaccines is the safety of concurrent administration of multiple antigens at a single visit — a question that has never been studied in a placebo-controlled trial. The Henry Ford Vaccinated vs. Unvaccinated Study is the only study in the source that compared children who received the full combined schedule against children who received nothing — and it found a 2.5× elevated chronic disease rate in vaccinated children. The institution blocked publication.
At a typical 2-month well-child visit, an infant may receive:
Total antigen exposure at a single visit: dozens of distinct antigens, multiple adjuvants, multiple preservatives — administered to an infant whose immune system is in early development.
No clinical trial has tested the safety of this concurrent administration against a no-vaccine control. Each vaccine's licensure trial tested only that vaccine against an active comparator (often another active vaccine). No trial has examined the combined biological effect of the full concurrent schedule against a no-vaccine baseline.
The post-licensure surveillance systems (VAERS, VSD (Vaccine Safety Datalink), V-SAFE) cannot reliably detect the cumulative effect of concurrent administration because they have no comparison cohort that received zero vaccines.
The Henry Ford Vaccinated vs. Unvaccinated Study is the most significant post-licensure study in the source for evaluating the cumulative effect of the combined schedule. Conducted by mainstream pro-vaccine scientists at Henry Ford Health System using electronic medical records:
Henry Ford Health System administration blocked submission of the study for publication. The research had been completed by the institution's own scientists using its own EMR data. The decision to block publication was administrative, not scientific.
This is the most direct empirical comparison of the combined CDC schedule against no vaccination available in the source. The findings support concern about the cumulative effect of combination vaccines and concurrent administration.
The CDC's stipulated 20 studies in the autism lawsuit did not address concurrent administration of multiple vaccines or the combined schedule effect. None examined Pediarix, Pentacel, Vaxelis, Kinrix, Quadracel, or any other combination product specifically. See Post-Licensure Safety Monitoring.
Post-licensure surveillance found that ProQuad (MMRV combined) was associated with approximately twice the febrile seizure risk of MMR + Varivax administered separately, particularly in the 12–23 month age group. The CDC modified its recommendation to favor separate MMR + Varivax injections at the first dose to reduce this risk.
This is one of the few documented cases of post-licensure surveillance leading to a CDC recommendation modification for a combination vaccine.
The source mentions several other vaccinated vs. unvaccinated studies that compared full-schedule vaccinated children against unvaccinated cohorts:
These studies have varying methodological quality (small sample sizes, selection bias) but generally find higher chronic disease rates in vaccinated cohorts. See Post-Licensure Safety Monitoring and Childhood Chronic Disease Trends for detail on each study.
Combination vaccines are subject to the same post-licensure surveillance limitations as their individual components. VAERS reports for combination products like Pediarix, Pentacel, and Vaxelis do exist but the systems' inability to identify cumulative-exposure signals limits their utility for evaluating combination-specific safety.
Combination Vaccines (Pre-Licensure), Henry Ford Vaccinated vs. Unvaccinated Study, Post-Licensure Safety Monitoring, Childhood Chronic Disease Trends
Frequently Asked Questions